Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Creative BioMolecules Inc. (CBMI), Enzon Inc. (ENZN) deal

The companies finalized their agreement to cross-license ENZN's Single-Chain Antigen-Binding (SCA) protein technology and CBMI's Biosynthetic

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE